Project Grant R01HL179780
Award Date
5/1/25
Completion Date
2/28/29
Dollars Obligated
$743K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Cleveland Clinic Lerner College Of Medicine Of Case Western Reserve University (M5QFLTCTSQN6)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44195, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will provide $2,980,450 to fund research conducted by the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. The research aims to structurally identify and characterize an unknown metabolite associated with increased risk of cardiovascular disease (CVD) and major adverse cardiovascular events. Using untargeted...
This federal Project Grant award of $915,924 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research focused on understanding how disruptions to early-life gut microbiome colonization can impair the development and function of key lung immune and epithelial cells. The research aims to elucidate how these microbiome-driven changes contribute to increased susceptibility to respiratory infections and the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $165,996 to The Leland Stanford Junior University to investigate the role of the gut microbiome in chronic heart failure with reduced ejection fraction. The key objectives are to: 1) examine the relationship between the gut microbial Bifidobacterium-based functional guild and heart failure severity/outcomes, and 2) elucidate...
This $2,061,249 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) will fund research to identify and characterize novel microbial metabolites, particularly microbial lipids ("xenolipids"), derived from the human gut microbiome. The key products and services to be delivered include: Expanding the catalog of microbial metabolites by leveraging...
This Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate the relationship between maternal obesity, gut microbiome, and cardiovascular disease in offspring. The $250,000 award supports a 4-year study at Colorado State University to determine if maternal gut dysbiosis and inflammatory signaling contribute to abnormal fetal programming and the development of cardiometabolic...
This $603,632 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to define the role of the gene PLA2G12B in regulating the assembly, metabolism, and cardiovascular disease risk of triglyceride-rich lipoproteins. The research is being conducted by The Johns Hopkins University, a leading private research institution, and leverages novel...
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) awarded a $226,784 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to the University of Cincinnati. The grant, awarded on May 20, 2024, with a completion date of November 30, 2024, supports research to determine how the gut microbiome-derived metabolite trimethylamine N-oxide (TMAO) contributes to the initiation and progression of abdominal aortic aneurysm (AAA) through...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $768,896 to the University of Toledo to investigate the role of conjugated bile acids as antihypertensive metabolites. The key objectives are to 1) determine why conjugated bile acids are depleted in hypertension, potentially due to specific gut microbiota, and 2) elucidate the mechanism by which conjugated bile acids, particularly...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,229,404 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Yale University to investigate the role of novel lysoplasmalogenase enzymes in regulating macrophage immunometabolic responses in cardiovascular disease. The project aims to elucidate how the LXR/miR-33/TMEM86A signaling pathway contributes to chronic vascular inflammation in atherosclerotic lesions. Yale will utilize cutting-edge genomic and metabolomic...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) provides $364,324 to The Leland Stanford Junior University to study the regulatory role of microbially-derived metabolites on the host immune system, particularly the impact on macrophages. The research aims to determine the metabolic pathways responsible for producing immune-associated microbial...